





## COMPASS Comprehensive Assay

a 1021 genes, targeted Next-Generation Sequencing (NGS) panel, designed to deliver personalized treatment decisions for multiple solid tumour types

Multiple Variant Types



\*Clinical Validation ongoing



ICI: Immune checkpoint inhibitor  
HRR: Homologous recombination repair  
PARP: Poly adenosine diphosphate-ribose polymerase

## Comprehensive

NGS of 1021 genes in a single test for treatment selection

## Actionable

Validated for clinically actionable genes for multiple cancer types

## Fast

Fast turnaround time for quick treatment decision

## Sample Requirements



Provide 10 unstained sections (5-10  $\mu\text{m}$  thick) on uncoated / uncharged slides\*



Provide 1 matching H&E stained slide with tumour region marked out



Tumour cellularity:  $\geq 30\%$   
Tumour region:  $\geq 25 \text{ mm}^2$

\*Additional 5 sections are required if tumour region  $< 25 \text{ mm}^2$

# mirxes

TO KNOW. TO ACT.

For more information on how COMPASS can support personalized treatment decisions, contact us at:

**Contact:**  
[contact@mdiagnosics.com](mailto:contact@mdiagnosics.com)  
+65 6950 3210

**Address:**  
30 Biopolis St, #09-05/06 Matrix,  
Singapore 138671